POMC and neoplasm: The efficacy of pasireotide, a second-generation SSA, seems controversially in CTP-BADX/NS patients, since, the use of pasireotide was associated with lowering of ACTH levels but a marginal impact on tumor volume [56–58]; also in our patients during pasireotide we observed and initial tumor shrinkage, but over the long-term, despite stabilization of ACTH levels, there was a progressive increase in tumor volume.